NVIDIA Corp‘s (NASDAQ:NVDA) AI ambitions extend beyond chips. The company disclosed a stake in Generate Biomedicines Inc in its latest Form 13F filing, backing a biotech whose long-term vision is nothing less than making biology programmable.
• NVIDIA stock is building positive momentum. Why is NVDA stock trading higher?
In an exclusive email interview with Benzinga, co-founder and CTO Gevorg Grigoryan said the company was founded on the conviction that “machine learning can make biology programmable,” making AI the operating logic behind every stage of its drug discovery platform rather than an add-on technology.
From Educated Guesses to Machine-Scale Discovery
Grigoryan said AI is transforming drug discovery by making scientific hypotheses abundant rather than scarce.
